183133-96-2 Cabazitaxel AKSci X7252
 
 
Loading Please Wait...
  X7252    AKSci Reference Standard
Cabazitaxel
, 98% (HPLC)
 
XRP6258
RPR-116258A
taxoid XRP6258




IDENTITY
CAS Number:183133-96-2
MDL Number:MFCD18827611
MF:C45H57NO14
MW:835.93
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:NMR, LCMS, FT-IR, HPLC, OR
Physical Form:White to off white powder
Melting Point:162-167°C
Optical Rotation:-18.5 (c=0.52 in H2O)
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO 100 mg/mL, Ethanol <1 mg/mL, Water <1 mg/mL
Application(s):A semi-synthetic derivative of a natural taxoid.

REVIEW

 Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2/M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, this agent is a poor substrate for the membrane-associated, multidrug resistance (MDR), P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. In addition, cabazitaxel penetrates the blood-brain barrier (BBB).

REFERENCES
[1]Michielsen DP, Braeckman JG, Denis L. Cabazitaxel for the treatment of prostate cancer. Expert Opin Pharmacother. 2011 Apr;12(6):977-82.
[2] Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2011 Mar 10;5:117-24.
[3] Figg WD 2nd, Figg WD. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol Ther. 2011 Jan 12;10(12):1233-4.
[4] Diéras V, Lortholary A, Laurence V et al. Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. Eur J Cancer. 2012 Sep 10. [Epub ahead of print].

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of March 23, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives >


PubChem
  @PubMed